Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human S1PR2 Antibodies:
anti-Mouse (Murine) S1PR2 Antibodies:
anti-Rat (Rattus) S1PR2 Antibodies:
Go to our pre-filtered search.
Human Polyclonal S1PR2 Primary Antibody for IF, IHC (p) - ABIN317633
Danieli-Betto, Peron, Germinario, Zanin, Sorci, Franzoso, Sandonà, Betto: Sphingosine 1-phosphate signaling is involved in skeletal muscle regeneration. in American journal of physiology. Cell physiology 2010
Show all 2 Pubmed References
Human Polyclonal S1PR2 Primary Antibody for EIA, IF - ABIN317746
Huang, Liu, Lan, Xie, Peng, Huang, Wang, Shen, Liu, Huang: Berberine reduces fibronectin expression by suppressing the S1P-S1P2 receptor pathway in experimental diabetic nephropathy models. in PLoS ONE 2012
Human Monoclonal S1PR2 Primary Antibody for CyTOF, FACS - ABIN4899079
Capitani, Patrussi, Trentin, Lucherini, Cannizzaro, Migliaccio, Frezzato, Gattazzo, Forconi, Pelicci, Semenzato, Baldari: S1P1 expression is controlled by the pro-oxidant activity of p66Shc and is impaired in B-CLL patients with unfavorable prognosis. in Blood 2012
Data suggest that activation of SR-BI (show SCARB1 Antibodies) by APOAI down-regulates sphingosine 1-phosphate/S1PR2-mediated inflammation in vascular endothelial cells by activating the PI3K (show PIK3CA Antibodies)/Akt (show AKT1 Antibodies) signaling pathway; oxidized-LDL does the opposite. (APOA1 (show APOA1 Antibodies) = apolipoprotein A-I (show APOA1 Antibodies); SR-BI/SCARB1 (show SCARB1 Antibodies) = scavenger receptor class B type I; S1PR2 = sphingosine 1-phosphate receptor 2; PI3K (show PIK3CA Antibodies) = phosphatidylinositol 3-kinase; Akt (show AKT1 Antibodies) = proto-oncogene c-akt (show AKT1 Antibodies))
S1PR2 mediates Rho activation in normal cells neighboring RasV12-transformed cells.
Sphingosine 1-phosphate-induced IL-8 (show IL8 Antibodies) gene expression is mainly regulated via S1PR(1 (show S1PR1 Antibodies)), and its secretion is regulated through S1PR(2) receptor subtype.
S1PR2 is repressed by FOXP1 (show FOXP1 Antibodies) in activated B-cell and germinal center B-cell DLBCL cell lines with aberrantly high FOXP1 (show FOXP1 Antibodies) levels; S1PR2 expression is further inversely correlated with FOXP1 (show FOXP1 Antibodies) expression in 3 DLBCL patient cohorts.
LXR-alpha (show NR1H3 Antibodies) might downregulate S1PR2 expression via miR (show MLXIP Antibodies)-130a-3p in quiescent HUVECs. Stimulation of TNF-alpha (show TNF Antibodies) attenuates the activity of LXR-alpha (show NR1H3 Antibodies) and results in enhanced S1PR2 expression.
S1PR2 plays a critical role in TCA-induced COX-2 (show COX2 Antibodies) expression and CCA (show FBN2 Antibodies) growth and may represent a novel therapeutic target for CCA (show FBN2 Antibodies).
both S1PR1 (show S1PR1 Antibodies) and S1PR2 play a pivotal role in hyperglycemia-induced EC dysfunction and endothelial injury by reducing and enhancing the production of oxidative stress.
AB1 displayed potency at least equivalent to JTE-013 in affecting signaling molecules downstream of S1P2.
Activation of S1PR2-calcium influx-RhoA (show RHOA Antibodies)/ROCK dominates the high-dose S1P (show MBTPS1 Antibodies)-induced endothelial monolayer hyperpermeability response.
Data show that sphingosine kinase SphK1 (show SPHK1 Antibodies) and sphingosine-1-phosphate (S1P (show MBTPS1 Antibodies)) receptors S1P1 (show S1PR1 Antibodies), S1P2, S1P3 (show S1PR3 Antibodies), and S1P5 (show S1PR5 Antibodies) were expressed from primary, up to recurrent and secondary glioblastomas, with sphingosine kinase SphK2 (show SPHK2 Antibodies) levels were highest in primary tumors.
Results provide evidence that S1PR2 plays an essential role in modulating proinflammatory cytokine production and osteoclastogenesis.
activation of S1P2 with a selective receptor agonist increases cell viability and reduces cisplatin-mediated cell death by reducing ROS (show ROS1 Antibodies). Cumulatively, these results suggest that S1P2 may serve as a therapeutic target for attenuating cisplatin-mediated ototoxicity.
S1P2 receptor is a key signaling molecule in the S1Pdependent inhibition of adipogenic differentiation.
S1PR2, as a critical receptor in macrophages, impairs phagocytosis and antimicrobial defense in the pathogenesis of sepsis.
These results suggest that S1PR2 and CXCR5 (show CXCR5 Antibodies) cooperatively regulate localization of Tfh cells in GCs (show UGCG Antibodies) to support GC responses
The sphingolipid receptor S1PR2 is a receptor for Nogo-a (show RTN4 Antibodies) repressing synaptic plasticity.
S1PR2 expression was increased in disease-susceptible regions of the CNS of female SJL EAE mice compared with their male counterparts.
IL-6 (show IL6 Antibodies) increased the number of osteoclast precursor cells in tibial bone marrow via up-regulating S1PR2, thus playing a crucial role in systemic bone loss induced by inflammation.
Sphingosine-1-phosphate receptor 2 protects against anaphylactic shock through suppression of endothelial nitric oxide synthase (show NOS3 Antibodies) in mice.
Data show that two S1P (show S1PR1 Antibodies) receptors, S1P2 and S1P3 (show S1PR3 Antibodies), are collectively essential mediators of eyelid closure during murine development.
This gene encodes a member of the G protein-coupled receptors, as well as the EDG family of proteins. This protein participates in sphingosine 1-phosphate-induced cell proliferation, survival, and transcriptional activation
sphingosine-1-phosphate receptor 2
, sphingosine 1-phosphate receptor 2-like
, S1P receptor 2
, S1P receptor EDG5
, S1P receptor Edg-5
, endothelial differentiation G-protein coupled receptor 5
, endothelial differentiation, sphingolipid G-protein-coupled receptor, 5
, sphingosine 1-phosphate receptor 2
, sphingosine 1-phosphate receptor Edg-5
, G-protein coupled receptor 13
, lysophospholipid receptor B2
, sphingosine-1-phosphate receptor S1P(2)
, G-protein coupled receptor H218